AD80 is a potent inhibitor of the ALK and EGFR kinases, making it valuable in cancer research, particularly in studies targeting non-small cell lung cancer and other malignancies driven by kinase mutations. It demonstrates strong activity against both wild-type and resistant forms of these kinases, including the EGFR T790M mutation, which is associated with resistance to earlier generation inhibitors. Due to its ability to cross the blood-brain barrier, AD80 is also explored for treating brain metastases in preclinical models. Its high selectivity and efficacy in suppressing tumor growth in vitro and in vivo make it a useful tool compound in oncology drug development and signaling pathway studies.